Synthetic and structure–activity studies of SP2577 and TCP towards LSD1 targeting PROTACs

Abstract

Lysine-specific histone demethylase 1A (LSD1) is involved in epigenetic regulation and is a viable drug target with a number of LSD1 inhibitors in clinical trials. We report synthetic and structure–activity studies of two LSD1 inhibitors, TCP and SP2577, in clinical trials towards PROTAC development. 16 Heterobifunctional molecules were synthesised based on TCP and SP2577. No LSD1 degraders were identified in HCT116 cells, however two TCP analogues functionalised from the phenyl ring with an aklyl and PEG linker in combination with a VHL ligand demonstrated potent LSD1 inhibition in vitro in the HDAC1-CoREST-LSD1 complex (43 nM and 63 nM respectively). Our findings provide important SAR data towards LSD1 PROTACs.

Graphical abstract: Synthetic and structure–activity studies of SP2577 and TCP towards LSD1 targeting PROTACs

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Research Article
Submitted
12 May 2025
Accepted
23 Jul 2025
First published
05 Aug 2025
This article is Open Access
Creative Commons BY license

RSC Med. Chem., 2025, Advance Article

Synthetic and structure–activity studies of SP2577 and TCP towards LSD1 targeting PROTACs

M. E. Coulson, J. K. S. Norris, S. A. Smith, J. P. Smalley, J. W. R. Schwabe, S. M. Cowley and J. T. Hodgkinson, RSC Med. Chem., 2025, Advance Article , DOI: 10.1039/D5MD00420A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements